STAAR Surgical Financials
STAA Stock | USD 28.55 1.87 7.01% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Debt Equity Ratio | 0.0138 | 0.0132 |
|
| |||||
Current Ratio | 5.84 | 5.5615 |
|
|
The essential information of the day-to-day investment outlook for STAAR Surgical includes many different criteria found on its balance sheet. An individual investor should monitor STAAR Surgical's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in STAAR Surgical.
Net Income |
|
STAAR | Select Account or Indicator |
Understanding current and past STAAR Surgical Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of STAAR Surgical's financial statements are interrelated, with each one affecting the others. For example, an increase in STAAR Surgical's assets may result in an increase in income on the income statement.
STAAR Surgical Earnings Geography
Please note, the presentation of STAAR Surgical's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, STAAR Surgical's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of STAAR Surgical's management manipulating its earnings.
STAAR Surgical Stock Summary
STAAR Surgical competes with ResMed, West Pharmaceutical, ICU Medical, Merit Medical, and Microbot Medical. STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California. Staar Surgical operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 692 people.Specialization | Health Care, Health Care Equipment & Services |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US8523123052 |
CUSIP | 852312305 |
Location | California; U.S.A |
Business Address | 25651 Atlantic Ocean |
Sector | Health Care Equipment & Supplies |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.staar.com |
Phone | 626 303 7902 |
Currency | USD - US Dollar |
STAAR Surgical Key Financial Ratios
Return On Equity | 0.054 | ||||
Profit Margin | 0.06 % | ||||
Operating Margin | 0.06 % | ||||
Price To Sales | 3.85 X | ||||
Revenue | 322.42 M |
STAAR Surgical Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 206.9M | 257.4M | 345.8M | 415.1M | 488.7M | 513.1M | |
Other Current Liab | 17.7M | 25.0M | 30.2M | 32.6M | 31.9M | 33.5M | |
Net Debt | (110.4M) | (141.7M) | (167.6M) | (55.4M) | (147.2M) | (139.8M) | |
Retained Earnings | (141.8M) | (135.9M) | (111.4M) | (72.4M) | (47.4M) | (49.7M) | |
Cash | 120.0M | 152.5M | 199.7M | 86.5M | 183.0M | 192.2M | |
Net Receivables | 31.0M | 35.2M | 43.5M | 62.4M | 98.0M | 102.9M | |
Inventory | 17.1M | 18.1M | 17.3M | 24.2M | 35.1M | 36.9M | |
Other Current Assets | 315K | 10.6M | 10.9M | 9.5M | 11.4M | 12.0M | |
Total Liab | 47.0M | 60.2M | 87.2M | 82.7M | 102.7M | 107.9M | |
Total Current Assets | 174.7M | 216.4M | 271.4M | 312.0M | 365.3M | 383.5M | |
Short Term Debt | 5.1M | 7.1M | 6.8M | 3.7M | 8.7M | 4.5M | |
Accounts Payable | 8.1M | 2.8M | 8.7M | 11.6M | 13.6M | 14.2M | |
Common Stock | 448K | 464K | 477K | 482K | 488K | 271.6K | |
Intangible Assets | 296K | 270K | 218K | 173K | 155.7K | 147.9K | |
Other Liab | 8.1M | 12.4M | 9.8M | 3.6M | 4.2M | 3.8M | |
Other Assets | 4.5M | 5.6M | 4.6M | 5.8M | 6.6M | 7.0M | |
Net Tangible Assets | 157.8M | 195.2M | 256.6M | 330.2M | 379.8M | 398.8M | |
Capital Surpluse | 204.9M | 289.6M | 304.3M | 338.2M | 388.9M | 240.9M |
STAAR Surgical Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 657K | 2.4M | 38.0 | 2.4M | 2.8M | 3.0M | |
Total Revenue | 150.2M | 163.5M | 230.5M | 284.4M | 322.4M | 338.5M | |
Gross Profit | 112.0M | 118.4M | 178.6M | 223.4M | 252.7M | 265.3M | |
Operating Income | 11.9M | 6.8M | 33.3M | 43.8M | 28.1M | 29.5M | |
Ebit | 11.9M | 6.8M | 33.3M | 43.8M | 28.1M | 29.5M | |
Ebitda | 16.1M | 9.9M | 37.0M | 48.3M | 33.2M | 34.9M | |
Cost Of Revenue | 38.2M | 45.1M | 51.8M | 61.0M | 69.8M | 73.3M | |
Income Before Tax | 13.0M | 8.3M | 31.3M | 45.8M | 33.7M | 35.4M | |
Net Income | 14.0M | 5.9M | 27.5M | 39.7M | 21.3M | 22.4M | |
Income Tax Expense | (1.0M) | 2.4M | 6.8M | 6.8M | 12.3M | 13.0M | |
Research Development | 25.3M | 31.9M | 33.9M | 36.0M | 44.4M | 46.6M | |
Tax Provision | (1.0M) | 2.4M | 6.8M | 6.8M | 12.3M | 13.0M | |
Net Interest Income | 988K | 238K | (38K) | 2.4M | 7.0M | 7.3M |
STAAR Surgical Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change In Cash | 16.0M | 32.5M | 47.3M | (113.2M) | 96.6M | 101.4M | |
Free Cash Flow | 15.6M | 12.5M | 30.3M | 17.6M | (3.6M) | (3.4M) | |
Depreciation | 3.7M | 3.1M | 3.6M | 4.5M | 5.1M | 3.0M | |
Other Non Cash Items | 2.2M | 3.4M | 2.1M | 2.3M | 2.2M | 2.1M | |
Capital Expenditures | 10.2M | 8.4M | 13.6M | 18.1M | 18.2M | 19.1M | |
Net Income | 14.0M | 5.9M | 24.5M | 39.0M | 21.3M | 22.4M | |
End Period Cash Flow | 120.0M | 152.5M | 199.7M | 86.5M | 183.0M | 192.2M | |
Change To Inventory | (950K) | (1.4M) | 66K | (7.9M) | (14.4M) | (13.6M) | |
Change Receivables | (1.9M) | (6.0M) | (4.5M) | (4.0M) | (3.6M) | (3.8M) | |
Net Borrowings | (2.0M) | (515K) | (1.6M) | (126K) | (113.4K) | (119.1K) | |
Change To Netincome | 8.9M | 14.1M | 18.2M | 21.3M | 24.5M | 25.7M | |
Investments | (10.2M) | (8.4M) | (13.6M) | (156.4M) | 74.3M | 78.1M |
STAAR Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining STAAR Surgical's current stock value. Our valuation model uses many indicators to compare STAAR Surgical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across STAAR Surgical competition to find correlations between indicators driving STAAR Surgical's intrinsic value. More Info.STAAR Surgical is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers reporting about 0.63 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for STAAR Surgical is roughly 1.59 . At present, STAAR Surgical's Return On Equity is projected to increase slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the STAAR Surgical's earnings, one of the primary drivers of an investment's value.STAAR Surgical's Earnings Breakdown by Geography
STAAR Surgical Systematic Risk
STAAR Surgical's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. STAAR Surgical volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on STAAR Surgical correlated with the market. If Beta is less than 0 STAAR Surgical generally moves in the opposite direction as compared to the market. If STAAR Surgical Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one STAAR Surgical is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of STAAR Surgical is generally in the same direction as the market. If Beta > 1 STAAR Surgical moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in STAAR Surgical Stock are looking for potential investment opportunities by analyzing not only static indicators but also various STAAR Surgical's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of STAAR Surgical growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
STAAR Surgical November 26, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of STAAR Surgical help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of STAAR Surgical. We use our internally-developed statistical techniques to arrive at the intrinsic value of STAAR Surgical based on widely used predictive technical indicators. In general, we focus on analyzing STAAR Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build STAAR Surgical's daily price indicators and compare them against related drivers.
Information Ratio | (0.14) | |||
Maximum Drawdown | 17.93 | |||
Value At Risk | (4.26) | |||
Potential Upside | 6.36 |
Complementary Tools for STAAR Stock analysis
When running STAAR Surgical's price analysis, check to measure STAAR Surgical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy STAAR Surgical is operating at the current time. Most of STAAR Surgical's value examination focuses on studying past and present price action to predict the probability of STAAR Surgical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move STAAR Surgical's price. Additionally, you may evaluate how the addition of STAAR Surgical to your portfolios can decrease your overall portfolio volatility.
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Transaction History View history of all your transactions and understand their impact on performance | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |